Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

Vaccine

Volumn 29, Issue 45, 2011, Pages 8049-8059

  Cox, Rebecca J ^a,b   Pedersen, Gabriel ^a   Madhun, Abdullah S ^a   Svindland, Signe ^b   Sævik, Marianne ^c   Breakwell, Lucy ^c   Hoschler, Katja ^c   Willemsen, Marieke ^d   Campitelli, Laura ^e   Nøstbakken, Jane Kristin ^a   Weverling, Gerrit Jan ^d   Klap, Jaco ^d   McCullough, Kenneth C ^f   Zambon, Maria ^c   Kompier, Ronald ^d   Sjursen, Haakon ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Parasitic and Immune mediated diseases Istituto Superiore di Sanità ^*

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

Antibody response; Cross reactivity; HI; Influenza H5N1; Matrix M; MN; SRH

Indexed keywords

ADJUVANT; HEMAGGLUTININ; INFLUENZA VACCINE; MATRIX M; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMOLYSIS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PAIN; VACCINATION; VACCINES, VIROSOME;

EID: 80053645706     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.042     Document Type: Article

References (44)

1. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(March (13)):1343-1351.
2. Hehme N., Engelmann H., Kunzel W., Neumeier E., Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002, 191(December (3-4)):203-208.
3. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(June (9272)):1937-1943.
4. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
5. Keitel W.A., Atmar R.L. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol 2007, 7(October (5)):484-490.
6. Haaheim L.R. Vaccines for an influenza pandemic: scientific and political challenges. Influenza Other Respiratory Viruses 2007, 1(2):55-60.
7. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004, 4(August (8)):499-509.
8. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(December (25)):2405-2413.
9. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6(October (5)):685-698.
10. WHO. Tables on the clinical trials of pandemic influenza prototype vaccines. 2010 [cited 2011 1603]. Available from: http://www.who.int/entity/vaccine_research/immunogenicity/immunogenicity_table.xls.
11. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(August (9587)):580-589.
12. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005, 191(April (8)):1210-1215.
13. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21(April (15)):1687-1693.
14. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(March (5)):667-675.
15. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008, 198(September (5)):642-649.
16. Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011;10(April (4)):401-3.
17. Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007, 6(October (5)):761-772.
18. Huckriede A., Bungener L., Daemen T., Wilschut J. Influenza virosomes in vaccine development. Methods Enzymol 2003, 373:74-91.
19. + cells and strong antibody responses in mice. Vaccine 2009, 27(December (52)):7367-7376.
20. Pedersen G, Major D, Roseby S., Wood J, Madhun AS, Cox RJ, Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respiratory Viruses 2011;(May), doi:10.1111/j.1750-2659.2011.00256.x.
21. Stephenson I., Wood J.M., Nicholson K.G., Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003, 70(July (3)):391-398.
22. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009, 4(2):e4384.
23. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(April (4)):937-943.
24. Products ECfP.M. Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96) March 1997, European Agency for the Evaluation of Medicinal Products.
25. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(May (9523)):1657-1664.
26. Rumke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26(May (19)):2378-2388.
27. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(September (9540)):991-997.
28. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358(June (24)):2573-2584.
29. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362(December (9400)):1959-1966.
30. Hehme N., Engelmann H., Kuenzel W., Neumeier E., Sanger R., et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103(July (1-2)):163-171.
31. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(July (Suppl 1)):S26-S38.
32. Herzog C., Hartmann K., Kunzi V., Kursteiner O., Mischler R., Lazar H., et al. Eleven years of Inflexal((R)) V - a virosomal adjuvanted influenza vaccine. Vaccine 2009, 27(July (33)):4381-4387.
33. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(February (13-14)):1732-1737.
34. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 2008, 3(1):e1401.
35. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15(August (8)):1252-1259.
36. Tsai C., Caillet C., Hu H., Zhou F., Ding H., Zhang G., et al. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 2009, 27(November (48)):6777-6790.
37. Nolan T., Richmond P.C., Formica N.T., Hoschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26(November (50)):6383-6391.
38. Wu J., Fang H.H., Chen J.T., Zhou J.C., Feng Z.J., Li C.G., et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009, 48(April (8)):1087-1095.
39. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010, 5(12):e15559.
40. Montomoli E., Capecchi B., Hoschler K. Correlates of protection against influenza. Influenza Vaccines Future 2011, 199-222.
41. CHMP. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application 2008.
42. + T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009, 106(March (10)):3877-3882.
43. WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases; 2007 [cited 2011 0316]. Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/RecAIlabtestsAug07.pdf.
44. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201(June (11)):1644-1653.